You are leaving Smmttx.com

You have selected a link that will take you to a site maintained by a third party who is solely responsible
for its contents.

Summit Therapeutics, Inc., is not responsible for the privacy notice of any third-party websites. We encourage you to read the privacy notice of every website you visit.

To stay on Summit’s website, click “Cancel” or click “Continue” to proceed.

Ivonescimab MOA

Ivonescimab
Mechanism of Action

Ivonescimab MOA

 

Ivonescimab: Most Advanced PD-1/VEGF Bispecific Antibody in Clinical Development the U.S. & EU.* Brings two validated mechanisms in oncology1,2,3 into ONE novel tetravalent molecule.

 

 

For additional information on the HARMONi or the HARMONi-3 clinical trials, please visit clinicaltrials.gov or contact medinfo@smmttx.com

 

1. Manegold et al., (2016); JTO 12:2.194-207.; 2. Pardoll, Drew M. (2012) Nature Reviews Cancer vol. 12,4 :252-64.; 3. Tamura et al., (2020) Med Oncol 37:2, 10.1007. 4. Zhao Y. et al., (August 2023) eClinicalMedicine vol 62: 102106.; 5. Zhou C. et al., Journal of Clinical Oncology 40, no. 16_suppl (June 01, 2022) 9040.; 6. Zhong T et al., (2022) Journal for ImmunoTherapy of Cancer 10(2) 521. 

Ivonescimab is an investigational therapy that is not approved by any regulatory authority.

*There are no known PD-1-based bispecific antibodies approved by the U.S. Food and Drug Administration (“FDA”) or the European Medicines Agency (“EMA”).